Assistant Professor at the University Medical Center Groningen. His research interest is in regulatory decision-making and knowledge transfer with a specific interest in risk communication and medication safety. His key publications are on the impact of Direct Healthcare Professional Communications on drug utilization, regulatory decision-making and on various interventions to improve medication safety. Current research projects include WEB-RADR focusing on patients’ and healthcare professionals’ views expectations of and views for two-way risk communication using a mobile app. Other projects include SCOPE joint action on risk communication by National Competent Authorities, CORE2 on improving risk communication in hospital settings, benefit-risk knowledge & communication in Sub Saharan Africa and usefulness of registries for regulatory purposes.
Peter Mol is also a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair) of EMA’s Scientific Advice Working Party. He is chair of the EMA Cross-Committee Task force on Registries (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mid=WC0b01ac0580961211).
He was vice-chair and cofounder of the Benefit Risk Assessment, Communication and Evaluation Special Interest Group (SIG) of the International Society of Pharmacoepidemiology (ISPE), cofounder of the risk communication SIG of the International Society of Pharmacovigilance (ISOP) and former executive committee member of the European Drug Utilisation Research Groups (EuroDURG).